Evidence map›Paper›PMID 41486656›Full record

Trial reportZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2025

[Phase Ⅲ, multicenter, randomized, double-blinded, positive-controlled trial on the efficacy and safety of maribavir compared with valganciclovir in the treatment of post-transplant cytomegalovirus infection: Subgroup analysis of AURORA Trial in the Chinese population].

L Xuan, H Huang, L P Xu, Y W Fu, F Chen, Y Wang, S Q Wang, L Dong, J Y Wu, D P Wu

Abstract readRandomized Controlled TrialClinical Trial, Phase IIIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

L XuanNanfang Hospital, Southern Medical University, Guangzhou 510515, China.
H HuangThe First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
L P XuPeking University People's Hospital, Beijing 100044, China.
Y W FuHenan Cancer Hospital, Zhengzhou 450008, China.
F ChenThe First Affiliated Hospital of Soochow University, Suzhou 215006, China.
Y WangThe First Affiliated Hospital of Soochow University, Suzhou 215006, China.
S Q WangGuangzhou First People's Hospital, Guangzhou 510180, China.
L DongTakeda Asia-Pacific Biopharmaceutical R&D Co., Ltd., Shanghai 200126, China.
J Y WuTakeda (China) International Trading Co., Ltd., Shanghai 200126, China.
D P WuThe First Affiliated Hospital of Soochow University, Suzhou 215006, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antiviral AgentsBenzimidazolesCytomegalovirus InfectionsGanciclovirRibonucleosidesAdolescentAdultDichlororibofuranosylbenzimidazoleDouble-Blind MethodEast Asian PeopleFemaleHematopoietic Stem Cell TransplantationHumansMaleMiddle AgedTreatment OutcomeAntiviral AgentsBenzimidazolesDichlororibofuranosylbenzimidazoleGanciclovirmaribavirRibonucleosidesValganciclovirCytomegalovirusHematopoietic stem cell transplantationMaribavirValganciclovir

Identifiers

PMID41486656
PMCPMC12791048

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.